why choose us

First received: December 5, 2022

Clinical Trial: Neuroprotective Effects of ACTH4-10PRO8-GLY9-PRO10

Study Status: Completed

Recruit Status: Completed

Condition: Ketamine-Induced Neurotoxicity

Study Type: Interventional


Official Title: Neuroprotective Effects of ACTH4-10PRO8-GLY9-PRO10 on The Ketamine-Induced Neurotoxicity In Neonatal Rats: Increased BDNF Expression And BDNF Serum Concentrations

Brief Summary: The compound ACTH4-10Pro8-Gly9-Pro10 is a synthetic analog molecule of an adrenocorticotropic hormone (ACTH) short fragment. That is free from hormonal effects and has neuromodulatory effects. We investigate the neuroprotective effects of ACTH4-10Pro8-Gly9-Pro10 can lessen neurotoxicity against ketamine in neonatal rats by looking at BDNF expression in the cortex and hippocampus tissue as well as BDNF blood levels.

Read more